BASKING RIDGE, N.J. and SHIRLEY, N.Y., May 6, 2021 /PRNewswire/ — Daiichi Sankyo, Inc. and American Regent, Inc., a Daiichi Sankyo Group company, today announced that the U.S. Food and Drug ...

First and only high-dose intravenous iron for iron deficiency anemia of various etiologies SHIRLEY, N.Y.--(BUSINESS WIRE)--American Regent, Inc., a subsidiary of Luitpold Pharmaceuticals, Inc. (a ...

Trials such as HEART-FID and AFFIRM-AHF have demonstrated positive treatment results for injectable ferric carboxymaltose in patients with heart failure and iron deficiency. On June 5, 2023, the FDA ...

Data from the HEART-FID study (NCT03037931) were presented today in a late-breaking research Hot Line session at the European Society of Cardiology Congress 2023. The results were simultaneously ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the first-ever IV iron replacement therapy to improve exercise capacity in adults with ...

Credit: Getty Images. Injectafer is an iron replacement product. The Food and Drug Administration (FDA) has expanded the approval of Injectafer ® (ferric carboxymaltose injection) to include patients ...

The US Food and Drug Administration (FDA) has approved ferric carboxymaltose injection (Injectafer) for the treatment of iron-deficiency anemia (IDA) in adults who either cannot tolerate or have not ...

Ferric carboxymaltose given as an IV bolus push injection is well tolerated and effective in correcting hemoglobin levels in hemodialysis patients with iron-deficiency anemia. Nearly 62% of patients ...

Credit: Getty Images. For patients weighing at least 50kg, Injectafer may be administered as a single dose option of 15mg/kg body weight up to a maximum of 1000mg intravenously. The Food and Drug ...